OncoSec Medical Incorporated
11
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
36.4%
4 terminated/withdrawn out of 11 trials
55.6%
-31.0% vs industry average
0%
0 trials in Phase 3/4
160%
8 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
Role: collaborator
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
Role: collaborator
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
Role: lead
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
Role: lead
IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Role: lead
Trial of pIL-12 Electroporation Malignant Melanoma
Role: lead
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
Role: lead
Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
Role: lead
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Role: collaborator
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment
Role: lead
Trial of pIL-12/MK-3475 in Metastatic Melanoma
Role: collaborator
All 11 trials loaded